203 related articles for article (PubMed ID: 31349996)
1. A meta-analysis of morbidity and mortality in primary cytoreductive surgery compared to neoadjuvant chemotherapy in advanced ovarian malignancy.
Bartels HC; Rogers AC; McSharry V; McVey R; Walsh T; O'Brien D; Boyd WD; Brennan DJ
Gynecol Oncol; 2019 Sep; 154(3):622-630. PubMed ID: 31349996
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.
Morrison J; Haldar K; Kehoe S; Lawrie TA
Cochrane Database Syst Rev; 2012 Aug; 2012(8):CD005343. PubMed ID: 22895947
[TBL] [Abstract][Full Text] [Related]
3. Morbidity and mortality in women with advanced ovarian cancer who underwent primary cytoreductive surgery compared to cytoreductive surgery for recurrent disease: a meta-analysis.
Bartels HC; Rogers AC; Postle J; Shields C; Mulsow J; Conneely J; Brennan DJ
Pleura Peritoneum; 2019 Jun; 4(2):20190014. PubMed ID: 31417960
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of neoadjuvant chemotherapy followed by interval cytoreductive surgery versus primary cytoreductive surgery for patients with advanced stage ovarian cancer during the initial treatment phase.
Tran AQ; Erim DO; Sullivan SA; Cole AL; Barber EL; Kim KH; Gehrig PA; Wheeler SB
Gynecol Oncol; 2018 Feb; 148(2):329-335. PubMed ID: 29273308
[TBL] [Abstract][Full Text] [Related]
5. Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer.
Meyer LA; Cronin AM; Sun CC; Bixel K; Bookman MA; Cristea MC; Griggs JJ; Levenback CF; Burger RA; Mantia-Smaldone G; Matulonis UA; Niland JC; O'Malley DM; Wright AA
J Clin Oncol; 2016 Nov; 34(32):3854-3863. PubMed ID: 27601552
[TBL] [Abstract][Full Text] [Related]
6. Systematic Review of Cytoreductive Surgery and Bevacizumab-Containing Chemotherapy in Advanced Ovarian Cancer: Focus on Safety.
Petrillo M; Nero C; Carbone V; Bruno M; Scambia G; Fagotti A
Ann Surg Oncol; 2018 Jan; 25(1):247-254. PubMed ID: 29134372
[TBL] [Abstract][Full Text] [Related]
7. Comparison of patient reported symptom burden on an enhanced recovery after surgery (ERAS) care pathway in patients with ovarian cancer undergoing primary vs. interval tumor reductive surgery.
Meyer LA; Shi Q; Lasala J; Iniesta MD; Lin HK; Nick AM; Williams L; Sun C; Wang XS; Lu KH; Ramirez PT
Gynecol Oncol; 2019 Mar; 152(3):501-508. PubMed ID: 30876495
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV).
Glasgow MA; Yu H; Rutherford TJ; Azodi M; Silasi DA; Santin AD; Schwartz PE
J Surg Oncol; 2013 Feb; 107(2):195-200. PubMed ID: 22648987
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.
Wright AA; Bohlke K; Armstrong DK; Bookman MA; Cliby WA; Coleman RL; Dizon DS; Kash JJ; Meyer LA; Moore KN; Olawaiye AB; Oldham J; Salani R; Sparacio D; Tew WP; Vergote I; Edelson MI
J Clin Oncol; 2016 Oct; 34(28):3460-73. PubMed ID: 27502591
[TBL] [Abstract][Full Text] [Related]
10. Factors associated with delivery of neoadjuvant chemotherapy in women with advanced stage ovarian cancer.
Hinchcliff E; Melamed A; Bregar A; Diver E; Clemmer J; Del Carmen M; Schorge JO; Alejandro Rauh-Hain J
Gynecol Oncol; 2018 Jan; 148(1):168-173. PubMed ID: 29128105
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of the age-adjusted Charlston co-morbidity index on peri-operative complications, adjuvant chemotherapy usage and survival in patients undergoing debulking surgery after neo-adjuvant chemotherapy for advanced epithelial ovarian cancer.
Phillips A; Singh K; Pounds R; Sundar S; Kehoe S; Nevin J; Elattar A; Balega J
J Obstet Gynaecol; 2017 Nov; 37(8):1070-1075. PubMed ID: 28741395
[TBL] [Abstract][Full Text] [Related]
12. Integrated prediction model of patient factors, resectability scores and surgical complexity to predict cytoreductive outcome and guide treatment plan in advanced ovarian cancer.
Piedimonte S; Bernardini MQ; Ding A; Laframboise S; Ferguson SE; Bouchard-Fortier G; Cybulska P; Avery L; May T; Hogen L
Gynecol Oncol; 2022 Sep; 166(3):453-459. PubMed ID: 35820987
[TBL] [Abstract][Full Text] [Related]
13. Intensive care admissions among ovarian cancer patients treated with primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery.
Pepin K; Bregar A; Davis M; Melamed A; Hinchcliff E; Gockley A; Horowitz N; Del Carmen MG
Gynecol Oncol; 2017 Dec; 147(3):612-616. PubMed ID: 28988028
[TBL] [Abstract][Full Text] [Related]
14. Analysis of clinical effects of neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Jiang Y; He W; Yang H; Su Z; Sun L
J BUON; 2018; 23(3):758-762. PubMed ID: 30003748
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemotherapy equalizes the optimal cytoreduction rate to primary surgery without improving survival in advanced ovarian cancer.
Taşkın S; Güngör M; Ortaç F; Öztuna D
Arch Gynecol Obstet; 2013 Dec; 288(6):1399-403. PubMed ID: 23775264
[TBL] [Abstract][Full Text] [Related]
16. Possible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancer.
Matsuo K; Matsuzaki S; Nusbaum DJ; Maoz A; Oda K; Klar M; Roman LD; Sood AK
Gynecol Oncol; 2021 Jan; 160(1):32-39. PubMed ID: 33196436
[TBL] [Abstract][Full Text] [Related]
17. Patients triaged to neoadjuvant chemotherapy have higher rates of sarcopenia: An opportunity for prehabilitation.
Fadadu PP; Polen-De CL; McGree ME; Weaver AL; Moynagh MR; Takahashi N; Langstraat CL; Cliby WA; Kumar A
Gynecol Oncol; 2021 Jan; 160(1):40-44. PubMed ID: 33109391
[TBL] [Abstract][Full Text] [Related]
18. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
[TBL] [Abstract][Full Text] [Related]
19. Oncologic Concerns regarding Laparoscopic Cytoreductive Surgery in Patients with Advanced Ovarian Cancer Submitted to Neoadjuvant Chemotherapy.
Favero G; Macerox N; Pfiffer T; Köhler C; da Costa Miranda V; Estevez Diz Mdel P; Fukushima JT; Baracat EC; Carvalho JP
Oncology; 2015; 89(3):159-66. PubMed ID: 25968072
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of neoadjuvant chemotherapy versus primary debulking surgery in patients with ovarian cancer: a meta-analysis.
Lv X; Cui S; Zhang X; Ren C
J Gynecol Oncol; 2020 Mar; 31(2):e12. PubMed ID: 31912670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
